» Articles » PMID: 16920924

CD4 T Cell-mediated Protection from Lethal Influenza: Perforin and Antibody-mediated Mechanisms Give a One-two Punch

Overview
Journal J Immunol
Date 2006 Aug 22
PMID 16920924
Citations 192
Authors
Affiliations
Soon will be listed here.
Abstract

The mechanisms whereby CD4 T cells contribute to the protective response against lethal influenza infection remain poorly characterized. To define the role of CD4 cells in protection against a highly pathogenic strain of influenza, virus-specific TCR transgenic CD4 effectors were generated in vitro and transferred into mice given lethal influenza infection. Primed CD4 effectors conferred protection against lethal infection over a broad range of viral dose. The protection mediated by CD4 effectors did not require IFN-gamma or host T cells, but did result in increased anti-influenza Ab titers compared with untreated controls. Further studies indicated that CD4-mediated protection at high doses of influenza required B cells, and that passive transfer of anti-influenza immune serum was therapeutic in B cell-deficient mice, but only when CD4 effectors were present. Primed CD4 cells also acquired perforin (Pfn)-mediated cytolytic activity during effector generation, suggesting a second mechanism used by CD4 cells to confer protection. Pfn-deficient CD4 effectors were less able to promote survival in intact BALB/c mice and were unable to provide protection in B cell-deficient mice, indicating that Ab-independent protection by CD4 effectors requires Pfn. Therefore, CD4 effectors mediate protection to lethal influenza through at least two mechanisms: Pfn-mediated cytotoxicity early in the response promoted survival independently of Ab production, whereas CD4-driven B cell responses resulted in high titer Abs that neutralized remaining virus.

Citing Articles

T4 Phage Displaying Dual Antigen Clusters Against H3N2 Influenza Virus Infection.

Liu S, Lin M, Zhou X Vaccines (Basel). 2025; 13(1).

PMID: 39852849 PMC: 11769387. DOI: 10.3390/vaccines13010070.


Antibody-mediated control mechanisms of viral infections.

Mackin S, Sariol A, Diamond M Immunol Rev. 2024; 328(1):205-220.

PMID: 39162394 PMC: 11661935. DOI: 10.1111/imr.13383.


Influenza Vaccination Mediates SARS-CoV-2 Spike Protein Peptide-Induced Inflammatory Response via Modification of Histone Acetylation.

Zuo Z, Mu Y, Qi F, Zhang H, Li Z, Zhou T Vaccines (Basel). 2024; 12(7).

PMID: 39066369 PMC: 11281326. DOI: 10.3390/vaccines12070731.


Lipid Nanoparticle with 1,2-Di-O-octadecenyl-3-trimethylammonium-propane as a Component Lipid Confers Potent Responses of Th1 Cells and Antibody against Vaccine Antigen.

Kawai A, Noda M, Hirata H, Munakata L, Matsuda T, Omata D ACS Nano. 2024; 18(26):16589-16609.

PMID: 38885198 PMC: 11223497. DOI: 10.1021/acsnano.4c00278.


Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections.

Zhuang Z, Zhuo J, Yuan Y, Chen Z, Zhang S, Zhu A Vaccines (Basel). 2024; 12(5).

PMID: 38793729 PMC: 11125924. DOI: 10.3390/vaccines12050478.